z-logo
Premium
Specifications for anti‐A and anti‐B in intravenous immunoglobulin: history and rationale
Author(s) -
Thorpe Susan J.
Publication year - 2015
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.13091
Subject(s) - hemolysis , medicine , antibody , adverse effect , titer , immunology , immunoglobulin g , pharmacology
Intravenous immunoglobulin (IVIG) products are generally safe and efficacious, although treatment‐related adverse reactions can occur in recipients. Adverse reactions include hemolysis in non–blood group O recipients linked to the passive transfer of anti‐A and/or anti‐B present in the fractionated immunoglobulin product. In light of the recent increase in reported cases of severe hemolysis associated with anti‐A and/or anti‐B, this article traces the development of pharmacopoeial specifications, tests, and reference reagents to control their titers in IVIG products.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here